ArticleTransplantation and cellular therapy2026
Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9].
Abstract readPublished Erratum
In one paragraph
Article in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum for
Authors and funding
31 authors.
Melissa R HinesDepartment of Pediatric Medicine, Division of Critical Care, St. Jude Children's Research Hospital, Memphis, Tennessee.
Tristan E KnightPediatric Hematology and Oncology, Seattle Children's Hospital and the University of Washington School of Medicine, Seattle, Washington.
Kevin O McNerneyCancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.
Mark B LeickCellular Immunotherapy Program and Blood and Marrow Transplant Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
Tania JainDivision of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Sairah AhmedDepartments of Lymphoma and Myeloma and Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Matthew J FrigaultCellular Immunotherapy Program and Blood and Marrow Transplant Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
Joshua A HillVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Michael D JainMoffitt Cancer Center, Tampa, Florida.
William T JohnsonDepartment of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Yi LinDivision Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Rochester, Minnesota.
Kris M MahadeoPediatric Transplantation and Cellular Therapy, Duke University, Durham, North Carolina.
Gabriela M MaronDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, Department of Pediatrics, University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee.
Rebecca A MarshUniversity of Cincinnati, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Sattva S NeelapuDepartments of Lymphoma and Myeloma and Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sarah NikiforowDivision of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Amanda K OmbrelloInflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.
Nirav N ShahBone Marrow Transplant and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Aimee C TalleurDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee and Department of Pediatrics, University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee.
David TuricekPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Anant VatsayanDivision of Blood and Marrow Transplantation, Children's National Health System, Washington, District of Columbia.
Sandy W WongUCSF Health Division of Hematology and Oncology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Marcela V MausCellular Immunotherapy Program and Blood and Marrow Transplant Program, Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
Krishna V KomanduriUCSF Health Division of Hematology and Oncology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Nancy BerlinerBrigham and Women's Hospital, Boston, Massachusetts.
Jan-Inge HenterDivision of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institute, Department of Paediatric Oncology, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Miguel-Angel PeralesDepartment of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Noelle V FreyDivision of Hematology-Oncology, Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
David T TeacheyDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Matthew J FrankDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Nirali N ShahPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: Nirali.Shah@nih.gov.
Funding
Immunotherapeutic approaches to treat pediatric hematologic malignanciesZIABC011823 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHAH, NIRALI · 2019 to 2025
$6.1MComprehensive Interrogation of Toxicity Profiles Associated with Novel CAR T-cell ConstructsZIABC012187 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHAH, NIRALI · 2024 to 2025
$1.6MIntramural NIH HHS ZIA BC011823Intramural NIH HHS ZIA BC012187
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.